Bristol‑Myers Squibb (BMY) entered into a partnership with Evinova on February 9, 2026 to deploy the company’s AI‑native clinical development platform across BMY’s global portfolio. The agreement includes the Cost Optimizer module of Evinova’s Study Designer, an AI engine that refines trial design, identifies productivity opportunities, and accelerates timelines, as well as the Unified Trial Solution, which integrates electronic data capture, telehealth, and remote patient monitoring to support decentralized, patient‑centric studies.
Evinova’s platform has demonstrated up to a 60 % improvement in patient experience, a six‑month acceleration in trial delivery, and a 32 % reduction in costs in prior deployments, according to data published in Nature Medicine. While BMY has not disclosed the financial terms of the deal, the partnership is expected to streamline processes, enhance data quality, and improve the patient and site experience throughout its development programs.
BMY’s move reflects a broader strategy to increase operational efficiency and speed up the delivery of new therapies. The company has previously partnered with Accenture on a Workbench platform and with Immunai to apply AI to immune data analysis, underscoring its commitment to integrating AI across R&D. Chief Medical Officer Dr. Cristian Massacesi emphasized that “digital tools and AI can help us overcome the long timelines, high costs, and frequent failures that have historically plagued drug development.”
The partnership does not yet specify a deployment timeline, but BMY intends to roll out the platform across its global portfolio in phases. The financial terms, including licensing fees and potential revenue sharing, remain undisclosed. BMY’s management has indicated that the platform will be a key component of its 2026 operational roadmap, which projects a 46‑47.5 billion‑dollar revenue range and an adjusted diluted EPS of 6.05‑6.35 for the year.
The collaboration positions BMY to capitalize on industry momentum toward AI‑driven clinical trials, potentially reducing the time and expense associated with development and improving the return on its substantial pipeline investments. By integrating Evinova’s AI tools, BMY aims to accelerate trial timelines, lower costs, and enhance patient engagement, thereby strengthening its competitive position as legacy portfolio revenues decline and growth‑portfolio drugs such as Eliquis and oncology candidates drive future growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.